U.S. Markets open in 9 hrs 15 mins

Atrion Corporation (ATRI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
576.60-15.50 (-2.62%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close592.10
Open593.51
Bid530.24 x 1400
Ask579.75 x 800
Day's Range572.91 - 590.10
52 Week Range572.91 - 764.49
Volume6,623
Avg. Volume6,860
Market Cap1.055B
Beta (5Y Monthly)0.16
PE Ratio (TTM)32.49
EPS (TTM)17.75
Earnings DateNov 09, 2020
Forward Dividend & Yield7.00 (1.18%)
Ex-Dividend DateNov 30, 2020
1y Target EstN/A
  • Atrion Corporation Declares Quarterly Cash Dividend
    GlobeNewswire

    Atrion Corporation Declares Quarterly Cash Dividend

    ALLEN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that its Board of Directors declared a quarterly dividend of $1.75 per share on its outstanding shares of Common Stock. This dividend will be payable on December 15, 2020 to stockholders of record at the close of business on December 1, 2020. Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.Contact:         Jeffery Strickland Vice President and Chief Financial Officer (972) 390-9800

  • Atrion Reports Third Quarter Results
    GlobeNewswire

    Atrion Reports Third Quarter Results

    ALLEN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that for the third quarter ended September 30, 2020 revenues totaled $33.8 million compared with $38.9 million for the same period in 2019. Net income for the third quarter of 2020 totaled $7.2 million as compared to $9.6 million for the same period in 2019, with diluted earnings per share for the third quarter of 2020 at $3.95 compared to $5.15 for the third quarter of 2019. Commenting on the Company’s quarterly results for the third quarter of 2020 compared to the same period last year, David A. Battat, President & CEO, stated, “Our results for the quarter were disappointing, with revenues down 13%, operating income down 27% and diluted EPS down 23%. In the second quarter of this year, our revenues began to weaken as our hospital and OEM customers reported a significant slowdown in surgeries due to the need for Covid-19 beds in hotspots, as well as continued patient reluctance to schedule surgeries. This trend accelerated in the third quarter, and we expect similar weakness in the fourth quarter of this year. Our customers are reporting that these declines in procedures are deferred rather than never to be performed, and, therefore, they expect to see a gradual recovery in 2021 as patients can no longer delay the need for care and hospitals adapt to expand their surgical capacity.” Mr. Battat continued, “We never make excuses for subpar results, but we remain optimistic. Despite the negative comparisons, the Company remains profitable and debt-free, while holding cash and short and long investments totaling $88.2 million as of September 30, 2020.”Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially.  Such statements include, but are not limited to, Atrion’s expectations regarding the demand for our products in the fourth quarter of 2020 and an increase in procedures in 2021. Words such as “expects,” “believes,” “anticipates,” “intends,” "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements.  Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.Contact: Jeffery Strickland   Vice President and Chief Financial Officer   (972) 390-9800       ATRION CORPORATION UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data)       Three Months Ended September 30, Nine Months Ended September 30,  2020 2019 2020 2019 Revenues$33,785  $38,883  $115,348  $120,600  Cost of goods sold 18,887   20,992   63,114   65,414  Gross profit 14,898   17,891   52,234   55,186  Operating expenses 7,315   7,441   22,891   22,732  Operating income 7,583   10,450   29,343   32,454           Interest and dividend income 303   733    1,161    1,896  Other investment income (loss)  678    (106)   5    265  Income before income taxes 8,564   11,077   30,509   34,615  Income tax provision (1,321)  (1,482)  (5,764)  (5,918) Net income $7,243  $9,595  $24,745  $28,697           Income per basic share$3.96  $5.17  $13.46  $15.48           Weighted average basic shares outstanding 1,829   1,855   1,839   1,854                    Income per diluted share$3.95  $5.15  $13.42  $15.40           Weighted average diluted shares outstanding 1,834   1,862   1,844   1,863                     ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands)       Sep 30, Dec 31, ASSETS2020  2019  (Unaudited)   Current assets:    Cash and cash equivalents$23,996  $45,048  Short-term investments 18,779   23,766  Total cash and short-term investments 42,775   68,814  Accounts receivable 17,747   18,886  Inventories 48,622   42,093  Prepaid expenses and other 4,013   2,545  Total current assets 113,157   132,338  Long-term investments 45,381   31,772  Property, plant and equipment, net 91,053   84,606  Other assets 13,441   13,315        $263,032  $262,031            LIABILITIES AND STOCKHOLDERS’ EQUITY         Current liabilities 12,699   11,274  Line of credit \--   \--  Other non-current liabilities 12,215   12,887  Stockholders’ equity 238,118    237,870        $263,032  $262,031

  • Update: Atrion (NASDAQ:ATRI) Stock Gained 61% In The Last Five Years
    Simply Wall St.

    Update: Atrion (NASDAQ:ATRI) Stock Gained 61% In The Last Five Years

    These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But in our...